United States Health

Oscar Health (NYSE:OSCR) reported Q2 2026 revenue of $4.88 billion and net income of $361.8 million, reversing the prior-year loss.

Planet Fitness (NYSE:PLNT) reported Q2 2026 revenue of $365.2 million, up 7.1%, and attributable net income of $67.1 million.

BD (NYSE:BDX) reported fiscal Q3 2026 revenue of $4.98 billion, up 5.4% as reported and 4.4% currency-neutral.

Kenvue (NYSE:KVUE) reported Q2 2026 net sales of $3.96 billion, up 3%, while diluted EPS increased to $0.24.

LifeMD (NASDAQ:LFMD) reported Q2 2026 revenue of $47.3 million and cut its full-year outlook after recording a $3.5 million adjusted EBITDA loss.

Moderna (NASDAQ:MRNA) received U.S. FDA approval for mFLUSIVA, an mRNA-based seasonal influenza vaccine for adults over 50.

Evotec (NASDAQ:EVO) entered a research partnership with Odyssey Therapeutics (NASDAQ:ODTX) to identify small-molecule candidates for autoimmune and inflammatory diseases.

Newmark (NASDAQ:NMRK) acquired L+P Immobilienbewertungs, adding more than 40 German valuation professionals, although the transaction’s financial terms were not disclosed.

Edgewell Personal Care (NYSE:EPC) reported fiscal third-quarter net sales of $570.1 million, up 1.7%, as North American organic sales returned to growth.

Elanco Animal Health (NYSE:ELAN) reported second-quarter revenue of $1.368 billion, up 10%, as Pet Health and Farm Animal sales increased.

CVS Health (NYSE:CVS) reported second-quarter revenues of $106.1 billion, representing a 7.3% increase driven by broad segment gains.

Lilly (NYSE:LLY) reported second-quarter revenue of $23 billion, up 48%, as demand for Mounjaro and Zepbound supported volume growth.